Gilead looks to Galapagos deal to double research capacity

Gilead looks to Galapagos deal to double research capacity

Source: 
Fierce Biotech
snippet: 
Daniel O’Day has framed Gilead’s $5.1 billion megadeal with Galapagos as a way to double its research capacity. The Gilead CEO told investors his company will benefit from having two drug discovery operations feeding into its clinical-phase pipeline.